Myelodysplastic Syndromes

May 8th 2024

Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.

April 30th 2024

The investigators said their new system makes it possible for researchers to leverage artificial intelligence even if they do not have expertise working with advanced software.

April 15th 2024

Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia.

April 11th 2024

The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant vs those who did not.